Astellas Pharma Inc. continually demonstrates their commitment to innovation and discovery in the biotech sector, as evidenced by various announcements. Firstly, Astellas forms an exclusive licensing agreement with
Evopoint Biosciences for
XNW27011, a promising antibody-drug conjugate targeting
CLDN18.2. This follows its acquisition of Evopoint's CLDN18.2-targeting ADC for $1.34 billion. The company also announced changes to their board of directors, and the indictment of an employee in China, though specifics are unclear. Astellas solidifies a joint venture with
YASKAWA focused on cell therapy manufacturing, while strengthening partnerships with companies like MBC BioLabs. Regulatory approval advancements were significant, including an expanded label for their IZERVAY product for Geographic Atrophy and the approval of novel gastric cancer therapeutic, VYLOY. Astellas also collaborates with Pfizer on XTANDI, demonstrating long-term survival in prostate cancer. The company commits to sustainability by employing IBM Envizi ESG Suite for their reporting. However, despite these positives, Astellas confronts a setback with the FDA, shaking up prospects, while revealing $1.1 billion impairment charges for Izervay.
Astellas Pharma Inc. News Analytics from Mon, 06 Nov 2023 08:00:00 GMT to Tue, 03 Jun 2025 15:00:00 GMT -
Rating 5
- Innovation 8
- Information 8
- Rumor -2
